16.37

0.18% 0.03

After Hours: 16.37

Theravance Biopharma Inc (TBPH)

Overview News Price History Option Chain Financials Discussions Forecast

Theravance Biopharma Inc stock is traded at $16.37, with a volume of 277.61K. It is up +0.18% in the last 24 hours and down -1.21% over the past month. Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.

Previous Close:

$16.34

Open:

$16.31

24h Volume:

277.61K

Relative Volume:

0.47

Market Cap:

$843.92M

Revenue:

$107.46M

Net Income/Loss:

$105.90M

P/E Ratio:

8.0736

EPS:

2.0276

Net Cash Flow:

$238.50M

1W Performance:

+0.92%

1M Performance:

-1.21%

6M Performance:

-11.42%

1Y Performance:

+72.50%

1-Day Range:

$16.18

$16.43

1-Week Range:

$16.01

$16.60

52-Week Range:

$9.10

$21.03

Theravance Biopharma Inc Stock (TBPH) Company Profile

Name

Theravance Biopharma Inc

Sector

Healthcare (1108)

Industry

Biotechnology (618)

Phone

650-808-6000

Address

UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN

Employee

Twitter

Next Earnings Date

2026-05-14

Latest SEC Filings

TBPH's Discussions on Twitter

Compare TBPH vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TBPH Theravance Biopharma Inc	16.37	842.38M	107.46M	105.90M	238.50M	2.0276
VRTX Vertex Pharmaceuticals Inc	434.52	110.03B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	638.88	67.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	806.46	50.76B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	297.45	40.12B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	151.56	32.68B	742.00K	-1.37B	-1.07B	-7.0731

Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-05-26	Downgrade	Oppenheimer	Outperform → Perform
Mar-04-26	Downgrade	B. Riley Securities	Buy → Neutral
Dec-03-25	Initiated	Oppenheimer	Outperform
Sep-12-25	Initiated	B. Riley Securities	Buy
Aug-06-24	Downgrade	Leerink Partners	Outperform → Market Perform
Apr-12-24	Initiated	BTIG Research	Buy
Jan-08-24	Downgrade	Evercore ISI	Outperform → In-line
May-23-22	Initiated	SVB Leerink	Outperform
Nov-05-21	Upgrade	JP Morgan	Underweight → Neutral
Sep-15-21	Downgrade	JP Morgan	Overweight → Underweight
Aug-25-21	Downgrade	Morgan Stanley	Overweight → Underweight
Aug-24-21	Downgrade	Cowen	Outperform → Market Perform
Oct-14-20	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jul-07-20	Initiated	JP Morgan	Overweight
Jun-15-20	Initiated	Morgan Stanley	Equal-Weight
May-13-20	Initiated	Cowen	Outperform
Jan-08-20	Reiterated	H.C. Wainwright	Buy
Nov-06-19	Upgrade	Robert W. Baird	Underperform → Neutral
Oct-29-19	Initiated	H.C. Wainwright	Buy
Mar-29-18	Resumed	Piper Jaffray	Overweight
Aug-17-17	Initiated	Evercore ISI	Outperform
Jun-16-17	Initiated	Cantor Fitzgerald	Overweight
May-11-17	Reiterated	Needham	Buy
Dec-21-16	Initiated	Needham	Buy
Nov-03-16	Initiated	Piper Jaffray	Overweight
Oct-12-16	Downgrade	Robert W. Baird	Neutral → Underperform
Aug-03-16	Downgrade	BofA/Merrill	Neutral → Underperform
Jun-20-16	Initiated	Guggenheim	Buy
Jun-20-16	Reiterated	Leerink Partners	Outperform
May-12-16	Initiated	Leerink Partners	Outperform
May-05-16	Downgrade	BofA/Merrill	Buy → Neutral
Feb-03-15	Upgrade	Robert W. Baird	Underperform → Neutral

View All

Theravance Biopharma Inc Stock (TBPH) Latest News

May 22, 2026

Theravance Biopharma (TBPH) CEO has shares withheld to cover RSU taxes - Stock Titan

May 22, 2026

Theravance Biopharma (NASDAQ: TBPH) CFO has 8,670 shares withheld for RSU taxes - Stock Titan

May 22, 2026

Theravance Biopharma (TBPH) SVP has shares withheld for RSU taxes - Stock Titan

May 22, 2026

Theravance Biopharma (TBPH) SVP has 8,829 shares withheld for RSU tax - Stock Titan

May 22, 2026

Theravance Biopharma (TBPH) SVP uses 5,678 shares to cover tax bill - Stock Titan

May 22, 2026

May 18, 2026

Theravance Biopharma (TBPH) Q4 earnings and revenues lag estimates - MSN

May 18, 2026

May 15, 2026

Behavioral Patterns of TBPH and Institutional Flows - Stock Traders Daily

May 15, 2026

May 13, 2026

Are Options Traders Betting on a Big Move in Theravance Biopharma Stock? - TradingView

May 13, 2026

May 11, 2026

BTIG Maintains Theravance Biopharma (TBPH) Buy Recommendation - MSN

May 11, 2026

May 09, 2026

Here's why Theravance Biopharma (TBPH) is a strong momentum stock - MSN

May 09, 2026

May 08, 2026

TBPH Q1 Earnings Beat Amid Strategic Restructuring & Pipeline Hurdle - sharewise.com

May 08, 2026

BTIG Maintains Theravance Biopharma(TBPH.US) With Buy Rating, Maintains Target Price $21 - Moomoo

May 08, 2026